SCHEMBL1677340

SCHEMBL1677340

Brc1nc(-c2ccco2)cs1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.67
HSD17B10 Q99714 7/20 0.67
CYP19A1 P11511 1/20 0.57
ALDH1A1 P00352 11/20 0.54
PKM P14618 5/20 0.54
KDM4E B2RXH2 5/20 0.54
RAB9A P51151 4/20 0.54
GFER P55789 2/20 0.54
KDM4C Q9H3R0 1/20 0.54
MEN1 O00255 7/20 0.51
KMT2A Q03164 7/20 0.51
ALOX15 P16050 5/20 0.51
HPGD P15428 4/20 0.51
LMNA P02545 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
POLB P06746 6/20 0.48
BLM P54132 5/20 0.48
CASP1 P29466 3/20 0.48
CASP7 P55210 3/20 0.48
L3MBTL1 Q9Y468 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7253210 0.80 CYP19A1 (0.72) MAPTHSD17B10CYP19A1ALDH1A1PKM
SCHEMBL653613 0.80 MAPT (1.00) MAPTHSD17B10CYP19A1ALDH1A1PKM
SCHEMBL13954988 0.74 MAPT (0.59) MAPTHSD17B10CYP19A1ALDH1A1PKM
SCHEMBL22761299 0.74 MAPT (0.64) MAPTHSD17B10CYP19A1ALDH1A1PKM
SCHEMBL14267937 0.74 MAPT (0.59) MAPTHSD17B10CYP19A1ALDH1A1PKM
SCHEMBL1677538 0.74 MAPT (0.59) MAPTHSD17B10CYP19A1ALDH1A1PKM
SCHEMBL13955047 0.74 MAPT (0.59) MAPTHSD17B10CYP19A1ALDH1A1PKM
SCHEMBL21823786 0.73 CYP19A1 (0.50) MAPTHSD17B10CYP19A1ALDH1A1PKM
SCHEMBL3065254 0.73 MAPT (0.57) MAPTHSD17B10CYP19A1ALDH1A1PKM
SCHEMBL9236747 0.72 KDM4E (0.50) MAPTHSD17B10CYP19A1ALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1921077-B1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KIRIN CO LTD (JP) 2017-07-26 EP disclosed
US-7928098-B2 Therapeutic and/or preventive agents for a sleep disorder KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-04-19 US disclosed
US-20100280023-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 2010-11-04 US disclosed
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-17 US disclosed
EP-1921077-A1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-05-14 EP disclosed
EP-1894930-A1 THIAZOLE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-03-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER HCRTR1, MTNR1A, HCRTR2 MAPT 2204/4885HSD17B10 125/4885CYP19A1 464/4885
US-20100280023-A1 THIAZOLE DERIVATIVES ADORA2A, ADORA3, GPR6 MAPT 3668/4885HSD17B10 1946/4885CYP19A1 2509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.